You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 3, 2026

Claims for Patent: 12,370,179


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 12,370,179
Title:Methods for treating hypertrophic cardiomyopathy
Abstract:Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram.
Inventor(s):Fady Malik, Stuart Kupfer, Stephen B. Heitner, Laura Ann Robertson, Lixin Meng, Anna Osmukhina, Qi Wohltman
Assignee: Cytokinetics Inc
Application Number:US18/909,401
Patent Claims: 1. A method of treating obstructive hypertrophic cardiomyopathy (oHCM) in a patient in need thereof, comprising: administering to the patient a first daily dose of Compound 1, or a pharmaceutically acceptable salt thereof, for a first time period, wherein the first daily dose is about 5 mg and the first time period is about 2 weeks; and based on one or more components of a first echocardiogram for the patient acquired after the first time period, administering to the patient a second daily dose of Compound 1, or a pharmaceutically acceptable salt thereof, for a second time period, wherein the second time period is about 2 weeks, wherein the one or more components of the first echocardiogram comprises a LVEF and a post-Valsalva LVOT-G, and wherein the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is about 10 mg when the LVEF of the first echocardiogram is at or above 55% and the post-Valsalva LVOT-G of the first echocardiogram is at or above 30 mmHg, or wherein the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is the same as the first daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, when either of the following conditions are met on the first echocardiogram: (1) the LVEF is at or above 50% and below 55%; or (2) the LVEF is at or above 55% and the post-Valsalva LVOT-G is below 30 mmHg.

2. The method of claim 1, wherein the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is administered to the patient for the second time period, the method further comprising, based on one or more components of a second echocardiogram for the patient acquired after the second time period and the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, administering to the patient a third daily dose of Compound 1, or a pharmaceutically acceptable salt thereof for a third time period, wherein the third time period is about 2 weeks; wherein the one or more components of the second echocardiogram comprises a LVEF and a post-Valsalva LVOT-G, and wherein the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is greater than the second daily dose of Compound 1 when the LVEF of the second echocardiogram is at or above 55% and the post-Valsalva LVOT-G of the second echocardiogram is at or above 30 mmHg, wherein the third daily dose is about 10 mg or about 15 mg, or wherein the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is lower than the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, or the administering of Compound 1, or the pharmaceutically acceptable salt thereof, to the patient is terminated, when the LVEF of the second echocardiogram is below 50%, or wherein the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is the same as the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, when either of the following conditions are met on the second echocardiogram: (1) the LVEF is at or above 50% and below 55%; or (2) the LVEF is at or above 55% and the post-Valsalva LVOT-G is below 30 mmHg.

3. The method of claim 2, wherein the administering of Compound 1, or the pharmaceutically acceptable salt thereof, to the patient is terminated when the LVEF of the second echocardiogram is below 50% and the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof is the same as the first daily dose of Compound 1.

4. The method of claim 2, wherein the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is the same as the first daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, when the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is higher than the first daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, and the LVEF of the second echocardiogram is below 50%.

5. The method of claim 2, wherein the first daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is about 5 mg of Compound 1, the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is about 5 mg or about 10 mg of Compound 1, and the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is about 5 mg, about 10 mg, or about 15 mg of Compound 1.

6. The method of claim 2, wherein the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is administered to the patient for the third time period, the method further comprising, based on one or more components of a third echocardiogram for the patient acquired after the third time period and the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, administering to the patient a fourth daily dose of Compound 1, or a pharmaceutically acceptable salt thereof, for a fourth time period, wherein the one or more components of the third echocardiogram comprises a LVEF and a post-Valsalva LVOT-G, and: wherein the fourth daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is greater than the third daily dose of Compound 1 when the LVEF of the third echocardiogram is at or above 55% and the post-Valsalva LVOT-G of the third echocardiogram is at or above 30 mmHg, wherein the fourth daily dose is about 10 mg or about 15 mg or about 20 mg, or wherein the fourth daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is lower than the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, or the administering of Compound 1, or the pharmaceutically acceptable salt thereof, to the patient is terminated, when the LVEF of the third echocardiogram is below 50%, or wherein the fourth daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is the same as the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, when either of the following conditions are met on the third echocardiogram: (1) the LVEF is at or above 50% and below 55%; or (2) the LVEF is at or above 55% and the post-Valsalva LVOT-G is below 30 mmHg.

7. The method of claim 6, wherein the administering of Compound 1, or the pharmaceutically acceptable salt thereof, to the patient is terminated when the LVEF of the third echocardiogram is below 50% and the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is the same as the first daily dose of Compound 1, or the pharmaceutically acceptable salt thereof.

8. The method of claim 6, wherein: the fourth daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is the same as the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, when the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is higher than the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, and the LVEF of the third echocardiogram is below 50%; or the fourth daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is the same as the first daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, when the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is the same as the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, and the LVEF of the third echocardiogram is below 50%.

9. The method of claim 6, wherein the first daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is about 5 mg of Compound 1, the second daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is about 10 mg of Compound 1, the third daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is about 15 mg of Compound 1, and the fourth daily dose of Compound 1, or the pharmaceutically acceptable salt thereof, is about 20 mg of Compound 1.

10. The method of claim 6, wherein the fourth time period is about 2 weeks.

11. The method of claim 1, wherein the patient is administered disopyramide or another antiarrhythmic medication during the treatment with Compound 1, or the pharmaceutically acceptable salt thereof.

12. The method of claim 1, wherein the patient has not been treated with disopyramide or an antiarrhythmic drug that has negative inotropic activity within 4 weeks prior to treatment with Compound 1, or the pharmaceutically acceptable salt thereof.

13. The method of claim 1, wherein the patient is a CYP2D6 poor metabolizer.

14. The method of claim 1, wherein the method does not include taking a blood sample of the patient.

15. The method of claim 1, wherein the method results in one or more of the following: improvement in mitral regurgitation, improvement in cardiac relaxation, beneficial cardiac remodeling, reverse cardiac remodeling, beneficial cardiac structural remodeling, beneficial cardiac functional remodeling, reversal of adverse cardiac remodeling, reduction in mean left ventricular mass index (LVMI), improvement in left ventricular (LV) filling pressures, reduction in left atrial volume index (LAVI), reduction in the categorical assessment of systolic anterior motion of the mitral valve leaflet, reduction in systolic anterior motion of the mitral valve leaflet, reduction in the frequency of eccentric mitral regurgitation, reduction in mitral regurgitation, reduction in lateral E/e′, reduction in lateral E/E, reduction in brain natriuretic peptide (BNP) and reduction in N-terminal prohormone of brain natriuretic peptide (NT-proBNP); or wherein the method results in one or more of the following: improvement in exercise capacity, improvement in peak oxygen uptake, improvement in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET), improvement in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), improvement in quality of life, improvement in quality of life as measured by PRO questionnaire, improvement in NYHA Functional Classification by one or more class(es), improvement in post-Valsalva left ventricular outflow tract gradient (LVOT-G), and improvement in total workload during CPET.

16. The method of claim 15, wherein the method results in one or more of: (a) change from baseline of ≥3.0 mL/kg/min in pVO2 and no worsening of NYHA Functional Class; (b) improvement in KCCQ-OSS or KCCQ-CSS by at least 5 points, at least 10 points, or at least 20 points; or (c) LVOT-G <30 mmHg, post-Valsalva LVOT-G <50 mmHg, and improvement in NYHA Functional Class by one or more class(es).

17. The method of claim 1, wherein administration of Compound 1, or the pharmaceutically acceptable salt thereof, is stopped when the LVEF is below 50%.

18. The method of claim 15, wherein the method results in change from baseline of >1.5 mL/kg/min in pVO2 and improvement in NYHA Functional Class by one or more class(es).

19. The method of claim 1, wherein the LVEF of the first echocardiogram is a biplane LVEF.

20. The method of claim 2, wherein the LVEF of the second echocardiogram is a biplane LVEF.

21. The method of claim 6, wherein the LVEF of the third echocardiogram is a biplane LVEF.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.